Carolus Therapeutics, Inc. is a biopharmaceutical company developing new treatments for cardiovascular and inflammatory diseases. Carolus develops first-in-class peptide and antibody-based therapeutics for these indications. The Company continues to move its two preclinical programs toward human clinical trials. These programs remain: peptide antagonists and antibodies to MIF (the “MIF Program”); and disruption of the RANTES/PF4 heterodimerization, using its proprietary peptide, CT-2009 (the “CT-2009 Program”).